-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vutiglabridin in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vutiglabridin in Non-Alcoholic Steatohepatitis (NASH) Drug Details: HSG-4112 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tipelukast in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tipelukast in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Tipelukast (KCA-757) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ecnoglutide in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ecnoglutide in Non-Alcoholic Steatohepatitis (NASH) Drug Details: XW-003 is under development for the treatment of non-alcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zelasudil in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zelasudil in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Zelasudil (RXC-007) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denifanstat in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Denifanstat in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Denifanstat (TVB-2640) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VK-2735 in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. VK-2735 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: VK-2735 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XW-004 in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XW-004 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: XW-004 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XW-014 in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XW-014 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: XW-014 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – YH-25724 in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. YH-25724 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: YH-25724 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CS-0159 in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CS-0159 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: CS-0159 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pemvidutide in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Pemvidutide (ALT-801) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ontamalimab in Non-Alcoholic Steatohepatitis (NASH)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ontamalimab in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Ontamalimab (TAK-647, SHP-647, PF-00547659) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Mosedipimod in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Mosedipimod (EC-18) is under development for the treatment of acute radiation...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sucunamostat in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Sucunamostat in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Sucunamostat (SCO-792) is under development for the treatment of obesity subjects...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Mitiperstat in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mitiperstat in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Mitiperstat is under development for the treatment of pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Epeleuton in Non-Alcoholic Steatohepatitis (NASH)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Epeleuton in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Epeleuton (AF-102) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Licogliflozin in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Licogliflozin in Non-Alcoholic Steatohepatitis (NASH)Drug Details:licogliflozin was under development for the treatment of nonalcoholic steatohepatitis (NASH)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Belapectin in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Belapectin in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Belapectin (GR-MD-02) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Icosabutate in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Icosabutate in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Icosabutate (PRC-4016; PRB-01022) is under development for the treatment of non-alcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ozempic in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ozempic in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Semaglutide (Ozempic / NN-9535 / NN-9931) is a...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.